4 Star analyst Buy Rating $9 Target On This Dirt Cheap Stock Is 500% Upside, And 5 Star Analyst Sees $8
$Esperion Therapeutics (ESPR.US)$ Esperion's Promising Future: Strategic Partnerships and Product Innovations Drive Buy Rating
Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst . Analyst Thomas Shrader from BTIG maintained a Buy rating on the stock and has a $9.00 price target.
Thomas Shrader has given his Buy rating due to a combination of factors that indicate a promising future for Esperion. One of the key reasons is the company’s potential to achieve profitability by late 2025, driven by a significant increase in Medicare patients willing to pay out-of-pocket costs, which suggests sustained demand for their products. Additionally, Esperion is exploring the development of a triple pill, which could enhance their product offerings and maintain engagement with healthcare providers.
Thomas Shrader has given his Buy rating due to a combination of factors that indicate a promising future for Esperion. One of the key reasons is the company’s potential to achieve profitability by late 2025, driven by a significant increase in Medicare patients willing to pay out-of-pocket costs, which suggests sustained demand for their products. Additionally, Esperion is exploring the development of a triple pill, which could enhance their product offerings and maintain engagement with healthcare providers.
Moreover, Esperion’s strategic partnerships for global expansion, such as those with NeoPharm and CSL, are expected to bolster their market presence in regions like Israel and Australia/New Zealand. These partnerships not only expand their reach but also provide opportunities for milestone payments and royalties. The positive real-world results from the MILO study further support the efficacy of their bempedoic acid franchise, which could drive future growth. Overall, these strategic initiatives and financial metrics contribute to Shrader’s optimistic outlook on Esperion’s stock.
Shrader covers the Healthcare sector, focusing on stocks such as Denali Therapeutics, Arcturus Therapeutics, and Verona Pharma. According to TipRanks, Shrader has an average return of 4.3% and a 36.08% success rate on recommended stocks.
5 Star analyst at Cantor Fitzgerald Kristen Kluska initiated coverage of Esperion with STRONG buy rating $8 price target.
-----------------------------------------------
The new Triple Combination pill will extend the patent for Esperion's drugs, NEXLIZET and NEXLETOL, until 2040. These drugs are now covered by most insurance companies. The expected results, shown in the slide image, are among the best in the worldwide cholesterol-lowering market, which generates about $20 billion in annual sales.
Personally, I know NEXLIZET works incredibly well. My mother switched from Amgen's REPATHA to NEXLIZET because she preferred not to have injections every two weeks. NEXLIZET also offers additional benefits that REPATHA doesn't, such as lowering hsCRP and improving PAD, both of which my mother deals with.hsCRP (high-sensitivity C-reactive protein)is a marker of inflammation in the body, and high levels are associated with an increased risk of heart disease.PAD (Peripheral Artery Disease)refers to the narrowing of the peripheral arteries, often in the legs, reducing blood flow and causing symptoms like pain or cramping.
My mother was also on Regeneron's PRALUENT before REPATHA, but it didn't lower her LDLc enough.
My mother can't take statins due to the common muscle aches and the increased blood sugar and insulin resistance they cause, especially since she's a type 2 diabetic. For me personally, I would never take a statin due to the numerous side effects, but my mother has had no issues with NEXLIZET.
Esperion is expected to reach profitability for the first time in 2025 and is currently trading at less than 1x its forward sales. I believe the company will soon be acquired by a major pharmaceutical company, the Triple combo pill will bring in a very large amount of yearly sales.
In the U.S statin alternative space, Amgen's REPATHA currently generates $1.2 billion in annual sales, with fourth-quarter U.S. sales reaching $315 million. Regeneron's PRALUENT brings in $252 million a year in U.S. sales. Esperion's NEXLIZET and NEXLETOL had $115 million in sales last year and are expected to see $178 million in U.S. sales for 2025, according to predictions from nine analysts. Additionally, government insurance now covers the costs for NEXLIZET and NEXLETOL, which is why my mother was able to get the drug at no cost.
I am invested in ESPR because I am confident it has a solid and growing future, regardless of whether it's acquired. The company is poised for success with strong sales projections and expanding coverage for its drugs, like NEXLIZET and NEXLETOL, which are gaining more recognition in the statin alternative space. With government insurance covering these medications and continued growth in the market, I believe Esperion's future remains very promising.
I saw this on Twitter account x.com/rumourbuy... about Daiichi Sankyo buying ESPR, and it makes sense to me. Daiichi Sankyo is taking over the manufacturing of ESPR's drugs as part of an agreement this year, and they are also developing the triple combination pill. Additionally, Daiichi is obligated to pay ESPR 25% royalties on all sales, which further aligns their interests. Given these factors, an acquistion seems like a logical next step for Daiichi to solidify their position in the cholesterol- lowering space.
$Amgen (AMGN.US)$ $Regeneron Pharmaceuticals (REGN.US)$ $Merck & Co (MRK.US)$ $Johnson & Johnson (JNJ.US)$ $Pfizer (PFE.US)$ $Moderna (MRNA.US)$ $NewAmsterdam Pharma (NAMS.US)$ $Moderna (MRNA.US)$ $Viking Therapeutics (VKTX.US)$ $Legend Biotech (LEGN.US)$ $Mineralys Therapeutics (MLYS.US)$ $AstraZeneca (AZN.US)$ $Novartis AG (NVS.US)$ $Exagen (XGN.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Market Insights
Discussing
Gold has rebounded to $3,300! It's time to get on board?
🎙️ Discussion: 1. Has it $Gold Futures (AUG5) (GCmain.US)$ rebounded to $3,300? Will the short-term trend continue to rise? 2. What factors
Options Newsman
May 6 20:45
S&P 500's Put/Call Ratio Hits 5-Year Low: Fear Fades and Bottom Near?
74502850 : I found this post interesting and came across it under my stock position in Merck, so I felt compelled to share my thoughts. As a cardiologist, I’ve recently started prescribing Bempedoic Acid (Nexletol) and the combination of Bempedoic Acid + Ezetimibe (Nexlizet) to my patients. It has now made its way into the guidelines, and I find it to be an effective option. I’ve been using Ezetimibe (Zetia) for quite some time, but on its own, it’s not particularly effective. In contrast, Nexlizet has shown impressive results, typically achieving a 40% reduction in cholesterol with no complaints of side effects.
I’ve also been trying patients on Nexlizet before moving to Repatha, and so far, it’s working well.
These days, many people are understandably more concerned about statin medications, especially when higher doses are required. I had a patient who experienced a heart attack followed by a stroke within the same week, primarily because he couldn’t tolerate the muscle pain from being on a high-dose statin. I think Esperion will do very well as company. I work at Heartplace Texas.
74502850 : Getting your cholesterol checked is important for several reasons:
Early Detection of Risk: Cholesterol levels can be a key indicator of your risk for cardiovascular diseases, including heart attacks, strokes, and peripheral artery disease. Often, high cholesterol doesn't have noticeable symptoms, so regular check-ups can help identify high levels before they cause serious issues.
Managing Heart Health: High cholesterol, particularly low-density lipoprotein (LDL) or "bad" cholesterol, can build up in your arteries, leading to plaque formation. This narrows and hardens the arteries, making it more difficult for blood to flow. Monitoring cholesterol levels helps you and your healthcare provider make informed decisions about managing your heart health.
Prevention of Complications: High cholesterol can lead to serious long-term complications like atherosclerosis (plaque buildup), which increases the risk of heart disease and stroke. By getting your cholesterol checked regularly, you can take steps to lower it through lifestyle changes or medication, potentially preventing more severe outcomes.
Risk Factors for Other Conditions: High cholesterol is often linked to other risk factors such as high blood pressure, diabetes, and obesity. Regular cholesterol checks can help spot potential interconnections and address them early on.
Tailored Health Plans: Knowing your cholesterol numbers enables your doctor to create a personalized plan to maintain or improve your heart health, which may include diet changes, exercise, or cholesterol-lowering medications if necessary.
Regular cholesterol checks are a simple but effective way to stay ahead of potential heart health issues, and they can be a vital part of maintaining overall wellness.
10xStockPicks 74502850 : I love you comment. Do you know Dr Sadi Raza? he is in Dallas location at Heart place. His friend Brinks2009 on twitter has shared his opinions about Nexlizet. Dr. Raza says he doesn't jump to PCSK9 injections without trying Nexlizet 1st
74502850 10xStockPicks : Yes, he is superb Physician, and has been featured in several magazines. He loves his sports.